Polaryx Therapeutics (PLYX) Current Assets (2024 - 2026)

Polaryx Therapeutics (PLYX) has reported Current Assets for 3 consecutive years, with $11.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets changed N/A year-over-year to $11.8 million in Q2 2026; TTM through Jun 2026 was $11.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.2 million, up 3.38% from the prior year.
• Current Assets was $11.8 million for Q2 2026 at Polaryx Therapeutics, up from $3.5 million in the prior quarter.
• Over five years, Current Assets peaked at $11.8 million in Q2 2026 and troughed at $3.5 million in Q1 2026.
• A 3-year average of $6.4 million and a median of $5.1 million in 2024 frame the typical range for Current Assets.
• The widest YoY moves for Current Assets: up 3.38% in 2025, down 3.38% in 2025.
• Over 3 years, Current Assets stood at $5.0 million in 2024, then rose by 3.38% to $5.2 million in 2025, then surged by 128.47% to $11.8 million in 2026.
• The last three Current Assets figures came in at $11.8 million (Q2 2026), $3.5 million (Q1 2026), and $5.2 million (Q4 2025), per Business Quant data.